focus -WSS

focus

author：fashion 2025-09-30 21:58:01 - browse：77

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth quarter:

The Food and Drug Administration’s decision in June to grant conditional approval to a gene therapy for Duchenne muscular dystrophy was a watershed moment for the treatment of the neuromuscular disease, and a big win for its maker, Sarepta Therapeutics. Confirming the gene therapy’s benefit — and potentially broadening its use to include older boys — will be determined by a Phase 3 clinical trial that will read out later this quarter.

Pfizeris developing its own gene therapy for Duchenne in a fully enrolled Phase 3 study with final results expected in 2024. But before the verdict is revealed, Pfizer intends to conduct an interim analysis later this quarter. The most likely outcome of this early look will be a determination to continue the study to its completion. But surprises — including an early stop for overwhelming efficacy — can’t be ruled out.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： What it’s like to watch children die of measles

WSS

RaDonda Vaught links Vanderbilt hospital issues to patient death

First U.S. drug developed to treat liver disease MASH is approved

Former medical device CEO who sold dummy, plastic parts convicted of fraud

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Just how do doctors, lawmakers, and the public define abortion?

Change Healthcare cyberattack prompts Medicare loan program

hotspot

focus

hotspot

In Memoriam: Notable people who died in 2023

First U.S. drug developed to treat liver disease MASH is approved

Supreme Court strikes down use of affirmative action

Change Healthcare outage fallout shows need for new oversight

Continuity nursing helped my family in our darkest PICU moments

As AI in medicine takes off, can 'human in the loop' prevent harm?

Supreme Court strikes down use of affirmative action

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Peter Hotez and the public health issue of online harassment

As AI in medicine takes off, can 'human in the loop' prevent harm?

Wikipedia

As AI in medicine takes off, can 'human in the loop' prevent harm?

Change Healthcare outage fallout shows need for new oversight

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

Novo Nordisk obesity pill bests Wegovy in early trial

Boston's new lab space is opening empty

knowledge

knowledge

knowledge

hotspot